In a development that could fundamentally alter the drug approval landscape, the US Food and Drug Administration has completed its first successful implementation of generative AI for scientific reviews and announced plans for agencywide deployment by 30 June 2025.
The generative AI system for regulatory reviews has demonstrated remarkable efficiency, with the FDA saying in a press release that the technology processes and synthesizes information from submissions in a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?